{"id":"W3152878368","doi":"10.1016/j.annonc.2021.04.008","title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":418,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Foundation Medicine; Samsung; Genentech; EMD Serono; Otsuka Pharmaceutical; Chugai Pharmaceutical; Seagen; Incyte; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Merck KGaA; Sanofi; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Carboplatin; Internal medicine; Oncology; Lung cancer; Hazard ratio; Placebo; Chemotherapy; Progression-free survival; Cisplatin; Confidence interval; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005038271,0.00127176,0.002478253,0.0007887141,0.0006311986,0.001863016,0.001196274,0.001003626,0.01001114],"category_scores_gemma":[0.005883115,0.0008117108,0.00836359,0.001227968,0.0004496552,0.001209373,0.00108453,0.002262569,0.001356576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001617161,"about_ca_system_score_gemma":0.002844029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00273998,"about_ca_topic_score_gemma":0.009480119,"domain_scores_codex":[0.9968925,0.001590984,0.0003081695,0.0004122659,0.0003744595,0.0004216113],"domain_scores_gemma":[0.9982975,0.0006632015,0.0003526525,0.0002671167,0.0002298186,0.0001897227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8375004,0.001416607,0.03392805,0.008839036,0.03329128,0.0001996544,0.0001601236,0.002870849,0.003661805,0.0008052145,0.02153475,0.05579219],"study_design_scores_gemma":[0.602806,0.04158337,0.2544937,0.002516753,0.04561777,0.000408695,0.0002533864,0.00243172,0.002908081,0.002556043,0.0442078,0.0002166367],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7107851,0.04497316,0.008406923,0.002177957,0.001268759,0.04449179,0.1516534,0.0004288964,0.0358141],"genre_scores_gemma":[0.87529,0.00756911,0.006634732,0.002970048,0.0004716683,0.02720288,0.06924599,0.0001638791,0.01045166],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01001114,"threshold_uncertainty_score":0.0334906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07969916344976641,"score_gpt":0.3712988432856288,"score_spread":0.2915996798358624,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}